Streetbeat News

Earnings

STOK

Stoke Therapeutics reported Q2 losses of $0.69 per share, missing the analyst consensus estimate of $0.64 by 7.81%. This is a 9.52% decrease over losses from the same period last year. The company also reported quarterly sales of $2.48 million, missing the analyst consensus estimate of $3.44 million by 172.12%. This is a 176.79% decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:22 am

PLTR

Shares of Palantir Technologies, Inc. (NYSE:PLTR) rose moderately in pre-market trading on Monday, ahead of its Q2 results announcement. The company has been in the spotlight due to its AI opportunities. Wedbush analyst Daniel Ives initiated the stock with an Outperform rating and a $25 price target. Analysts expect the company to report earnings of $0.05 per share, a reversal from a loss of $0.01 per share a year ago, and a 12.6% YoY increase in topline to $532.71 million.

Portfolio Pulse from Shanthi Rexaline

August 07, 2023 | 11:21 am

PASG

Passage Bio (NASDAQ:PASG) reported Q2 losses of $(0.44) per share, beating the analyst consensus estimate of $(0.48) by 8.33 percent. This represents a 39.73 percent increase over losses of $(0.73) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:20 am

TNGX

Tango Therapeutics reported Q2 losses of $(0.23) per share, a 17.86% improvement from $(0.28) per share YoY. The company's cash, cash equivalents and marketable securities stand at $310.7M, expected to fund operations until 2026.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:18 am

TRHC

Tabula Rasa HealthCare (NASDAQ:TRHC) reported Q2 losses of $(0.38) per share, missing the analyst consensus estimate of $(0.14) by 171.43%. However, the company reported quarterly sales of $90.04 million, beating the estimate of $88.82 million by 1.37%. This represents a 24.02% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:14 am

VINC

Vincerx Pharma reported Q2 losses of $(0.52) per share, a 40.91% improvement from $(0.88) per share losses in the same period last year. The company also reported cash and cash equivalents of $6.68M.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:11 am

ACRS

Aclaris Therapeutics reported Q2 earnings per share (EPS) of $(0.42), beating the estimate of $(0.45) by 6.67%. However, the company's sales of $1.87M missed the estimate of $1.90M by 1.63%. The EPS is a 35.48% decrease from last year, while sales increased by 22.32% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:11 am

ELAN

Elanco Animal Health reported strong earnings and raised its 2023 financial guidance, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:11 am

VTRS

Viatris has reaffirmed its FY23 revenue guidance of $15.5B-$16B, which is in line with the consensus of $15.6B. The company also expects an adjusted EBITDA of $5.0B-$5.4B and free cash flow of $2.3B-$2.7B.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:08 am

AXSM

Axsome Therapeutics reported Q2 losses of $(1.54) per share, missing the analyst consensus estimate of $(1.24) by 24.19 percent. This is a 45.28 percent decrease over losses from the same period last year. However, the company reported quarterly sales of $46.70 million, beating the analyst consensus estimate of $40.19 million by 16.20 percent, a 429.48 percent increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 11:04 am